75 Billion Reasons To Own Google
Alphabet (Google’s parent) has significantly ramped up research and development spending in recent years. In 2022, Google spent about $39.5 billion on R&D, which jumped to $45.4 billion in 2023. This ~15% increase was driven largely by higher personnel costs (adding thousands of engineers) and one-time charges like office space consolidation.
R&D now represents roughly 15% of Google’s annual revenue, » Read more about: 75 Billion Reasons To Own Google »
Read More
32% Gain In 11 Weeks Starts Now?
What are the odds that a boring consumer stock is about to skyrocket? It’s hard to predict major moves in advance unless you have an edge or an insight. And that’s precisely what the historical chart pattern of Ollie’s Bargain Outlet Holdings stock shows.
You see over the next 3 months, Ollie’s has historically gone on a tear,
» Read more about: 32% Gain In 11 Weeks Starts Now? »
Read More
Perfect Time To Bet The Farm On Vegas Stock?
Five years ago, the stock we are about to discuss was trading pretty much where it sits today. Between then and now, though, it’s plunged in value by 75% during the COVID era, and rallied 10x from those lows before losing about 75% again to trade close to where it’s at today.
With all that volatility,
» Read more about: Perfect Time To Bet The Farm On Vegas Stock? »
Read More
1 Digital Healthcare Stock To Avoid
Health services IT company TRxADE HEALTH, Inc. (NASDAQ:MEDS) played a vital role during the pandemic, making remote care and tests available to patients with its digital healthcare wing. While the effects of the pandemic are largely in the rearview mirror, TRxADE remains a prominent player in the pharmaceutical industry.
» Read more about: 1 Digital Healthcare Stock To Avoid »
Read More
Is Tesla Breaking Out?
When CEO Elon Musk reported Tesla’s latest earnings results this week, few were excited by the numbers.
In fact, the share price immediately fell off a cliff in after-hours trading to $356 per share but within minutes a sharp bounce back occurred and, in the virtual blink of an eye, the share price was back over $400 per share.
» Read more about: Is Tesla Breaking Out? »
Read MoreThe Burst
1 Organ Transplant Disruptor to Buy on the Dip
TransMedics (NASDAQ:TMDX) is an innovative biotechnology company that may well have the potential to disrupt the $11 billion organ transplant industry.
The company’s unique organ care system technology protects and monitors donor organs before they are transplanted into patients, resulting in improved organ health and outcomes. TransMedics also provides logistical services,
» Read more about: 1 Organ Transplant Disruptor to Buy on the Dip »
Read MoreThe Spotlight
Will This $20 Million Bet Pay Off?
A report just came out that one trader bet a massive $20 million on a single stock rising by 30% on its next earnings report. That stock is, drumroll, artificial intelligence favorite, Nvidia.
The bet was made by purchasing strike 1180 call options on Nvidia for the June expiration, meaning if NVDA share price rise were to rise above that level on expiration day,
» Read more about: Will This $20 Million Bet Pay Off? »
Read MoreThe Daily
Here's Why Aehr Test Systems Stock Had a Wild Ride in the First Half of 2025
Key Points
-
Aehr’s traditional end markets are suffering from a slowdown in electric vehicle investment.
-
The company has successfully opened up new markets that could potentially be far larger than its core silicon carbide end market.
» Read more about: Here's Why Aehr Test Systems Stock Had a Wild Ride in the First Half of 2025 »